Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

Afsaneh Keyhani; Yang O. Huh; David Jendiroba; Lance Pagliaro; Jorge Cortez; Sherry Pierce; Michael Pearlman; Elihu Estey; Hagop Kantarjian; Emil J. Freireich

doi:10.1016/S0145-2126(99)00147-2

Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

Afsaneh Keyhani, Yang O. Huh, David Jendiroba, Lance Pagliaro, Jorge Cortez, Sherry Pierce, Michael Pearlman, Elihu Estey, Hagop Kantarjian, Emil J. Freireich

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P<0.001), but was similar among ALL subtypes (56.6%; P=0.69). Ph+ ALL and AML with t(15;17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.

Original language	English (US)
Pages (from-to)	153-159
Number of pages	7
Journal	Leukemia Research
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/S0145-2126(99)00147-2
State	Published - Feb 2000

Keywords

Acute leukemia
CD38
Clinical outcome
Prognosis
Survival

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S0145-2126(99)00147-2

Cite this

@article{9329e5ecd0414541894c5979039548dc,

title = "Increased CD38 expression is associated with favorable prognosis in adult acute leukemia",

abstract = "CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P<0.001), but was similar among ALL subtypes (56.6%; P=0.69). Ph+ ALL and AML with t(15;17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.",

keywords = "Acute leukemia, CD38, Clinical outcome, Prognosis, Survival",

author = "Afsaneh Keyhani and Huh, {Yang O.} and David Jendiroba and Lance Pagliaro and Jorge Cortez and Sherry Pierce and Michael Pearlman and Elihu Estey and Hagop Kantarjian and Freireich, {Emil J.}",

year = "2000",

month = feb,

doi = "10.1016/S0145-2126(99)00147-2",

language = "English (US)",

volume = "24",

pages = "153--159",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

AU - Keyhani, Afsaneh

AU - Huh, Yang O.

AU - Jendiroba, David

AU - Pagliaro, Lance

AU - Cortez, Jorge

AU - Pierce, Sherry

AU - Pearlman, Michael

AU - Estey, Elihu

AU - Kantarjian, Hagop

AU - Freireich, Emil J.

PY - 2000/2

Y1 - 2000/2

N2 - CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P<0.001), but was similar among ALL subtypes (56.6%; P=0.69). Ph+ ALL and AML with t(15;17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.

AB - CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P<0.001), but was similar among ALL subtypes (56.6%; P=0.69). Ph+ ALL and AML with t(15;17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.

KW - Acute leukemia

KW - CD38

KW - Clinical outcome

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0034142647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034142647&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(99)00147-2

DO - 10.1016/S0145-2126(99)00147-2

M3 - Article

C2 - 10654451

AN - SCOPUS:0034142647

SN - 0145-2126

VL - 24

SP - 153

EP - 159

JO - Leukemia Research

JF - Leukemia Research

IS - 2

ER -

Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this